Strategic Development of Neuronal Stem & Progenitor Cell Products

Table of Contents

I. Background

• A. Neuronal Stem & Progenitor Cells
• B. Language Surrounding Neuronal Stem & Progenitor Cells
• C. Regulation of Neuronal Stem & Progenitor Cells
• D. Brief Product Background

II. Applications

• A. Basic Research
  • 1. Developmental Biology
  • 2. Adult Biology
• B. Drug Discovery Applications
• C. Drug Delivery Applications
• D. Neural Toxicology Assessment
• E. Neural Transplantation
• F. Brain Tumor Research

III. Application Priorities

• A. Overall
  • 1. Cell-Based Therapies: Greatest shared priority across research community
  • 2. Standardized Neural Toxicology Assays: Deserve proportionally more attention
• B. Breakdown of Neuronal Stem/Progenitor Cell Therapy, by Disorder
  • Parkinson' s
  • Brain Tumor / Glioma
  • Stroke
  • Spinal Cord Injury
  • Alzheimer' s
  • Other
  • Huntington' s
  • Multiple Sclerosis (MS)
  • Epilepsy
  • Amyotrophic Lateral Sclerosis (ALS)
  • Schizophrenia
  • Cerebral Palsy
• C. By Segment
  • 1. Academic
  • 2. Biotech
  • 3. Pharma

IV. Patents

• A. Key U.S. Neuronal Stem and Progenitor Cell Patents
• B. Additional U.S. Patents
• C. Additional European Patents

V. Projected 5-Year Market Growth

• A. Scientific Publication Analysis
  • 1. Neural vs. Neuronal Products
  • 2. Stem vs. Progenitor Cell Products
  • 3. Five-Year Growth Projections
  • 4. Conclusions from Data
• B. Grant Rate Analysis
  • 1. Neural vs. Neuronal Products
  • 2. Stem vs. Progenitor Cell Products
  • 3. Five-Year Growth Projections
  • 4. Conclusions from Data
• C. Patent Analysis
  • 1. Neural vs. Neuronal Products
  • 2. Stem vs. Progenitor Cell Products
  • 3. Five-Year Growth Projections
  • 4. Conclusions from Data

VI. Competitors: Suppliers of Neuronal Stem & Progenitor Cell Products, including Products Offered

• A. Millipore, Inc.
• B. Stem Cell Technologies
• C. AlphaGenix, Inc.
• D. R&D Systems
• E. Cell Applications
• F. SA Biosciences
• G. ScienCell
• H. Neuromics
• I. Amaxa
• J. Invitrogen
• K. Sigma Aldrich
• L. Orion (no longer in existence)

VII. Specialty Pharmaceutical Companies: Neuronal Stem & Progenitor Cell Therapies

• A. Neuralstem, Inc
• B. NeuroNova AB
• C. NeuroGeneration

VIII. Breakdown of Stem Cell Research Activity by Cell Type

• Embryonic SCs
• Hematopoietic SCs
• Mesenchymal SCs
• Neural Stem & Progenitor Cells
• Umbilical Cord SCs
• Cancer SCs
• Other SCs
• Fetal SCs

IX. Potential Labs/Customers

• A. Academic Labs
• B. Private Labs
• C. Commercial Labs
• D. Government Labs

X. Product Ideas & Suggestions

• A. Product Categories
  • 1. Cells & Tissue
    • a. Fetal-Derived Neural Stem Cells
    • b. Adult-Derived Neural Stem Cells
    • c. Fetal-Derived Immortalized Neural Stem Cells
    • d. Cryopreserved Embryonic Neurospheres
    • e. Embryonic Stem Cell Derived Neural Progenitors
    • f. Embryonic Primary Neuronal Tissue
    • g. NSC Differentiated Progeny Cells
  • 2. Kits
    • a. Kits for Analysis of NSC Differentiated Progeny
    • b. Stem Cell Functional Kits
    • c. Neuronal Stem Cell Phenotyping Kits
    • d. Neural Stem Cell Expansion Kits
    • e. Neural Stem Cell Differentiation Kits
    • f. Neural Stem Cell Blotting Kits
  • 3. Media: Maintenance, Differentiation, Expansion, & Freezing Medium
  • 4. Growth Factors
  • 5. Markets: Markers for Neural Stem Cells & Differentiated Progeny
  • 6. PCR Arrays
  • 7. Nucleofection Tools
  • 8. Neural Toxicity Assessment
• B. Product Suggestions
  • 1. Neural Toxicity Assessment Products (an untapped niche)
  • 2. Species-Specific Opportunities
  • 3. Areas of Underdeveloped Competition
  • 4. NSC Derived from Novel Sources
  • 5. Neural Rosette Cells (R-NSCs)